Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been given an average recommendation of “Hold” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.33.

Separately, StockNews.com initiated coverage on Syros Pharmaceuticals in a research note on Friday. They issued a “sell” rating for the company.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.05 on Tuesday. The stock has a market capitalization of $1.23 million, a P/E ratio of -0.02 and a beta of 1.31. The business has a 50 day simple moving average of $0.16 and a two-hundred day simple moving average of $0.83. Syros Pharmaceuticals has a 12 month low of $0.03 and a 12 month high of $6.93.

Institutional Investors Weigh In On Syros Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Two Sigma Securities LLC purchased a new position in Syros Pharmaceuticals in the fourth quarter worth approximately $25,000. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the 3rd quarter valued at $34,000. Finally, Exome Asset Management LLC lifted its position in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.